DCVax-L
A personalised vaccine made from the patient's own immune cells and tumour. Its 20-year-old phase 3 trial reported longer survival, but the way the result was analysed has divided the field.
DCVax-L is made by Northwest Biotherapeutics. Its phase 3 (NCT00045968, enrolled 2007-2015, n=331) published in JAMA Oncology 2023 using an external control comparison after a protocol change from PFS to OS: median OS 19.3 vs 16.5 months (newly diagnosed) and 13.2 vs 7.8 months (recurrent) versus matched external controls. Because almost all placebo patients crossed over and the primary endpoint was changed post hoc, most neuro-oncologists regard the evidence as inconclusive. UK MHRA marketing application submitted December 2023; it was still not FDA-approved in September 2026.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- Listed at phase 3 rather than approved; the external-control design and endpoint change are the reasons this remains contested.
Latest papers
topQuery for this drug: (TITLE:"DCVax-L" OR ABSTRACT:"DCVax-L") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DCVax-L, not a curated reading list.
Pages like this
not linked directly; found by shared links- CompanyGritstone bio
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- PersonYuquan Wei
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- PersonNina Bhardwaj
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- PersonRobert A. Fenstermaker
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
- InstitutionUniversity of Florida Health Cancer Center
Shares Personalised neoantigen (mRNA) vaccines, Glioma & glioblastoma.
- IdeaVaccinate against the resistance mutation before it takes over
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines.
- InstitutionComprehensive Cancer Center Tübingen-Stuttgart
Shares Off-the-shelf cancer vaccines, Personalised neoantigen (mRNA) vaccines, Glioma & glioblastoma.
- ProductRindopepimut
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.